This Article Full Text (PDF) All Versions of this Article: 1076029607305099v1 14/3/332    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Moore, G. W. Articles by Savidge, G. F. PubMed PubMed Citation Articles by Moore, G. W. Articles by Savidge, G. F. Social Bookmarking                   What's this?

The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies

Centre for Haemostasis and Thrombosis (Haemophilia Reference Centre), St Thomas' Hospital, London, England, gary.moore{at}gstt.nhs.uk

Savita Rangarajan, FRCPath

Centre for Haemostasis and Thrombosis (Haemophilia Reference Centre), St Thomas' Hospital, London, England

Geoffrey F. Savidge, MD

Centre for Haemostasis and Thrombosis (Haemophilia Reference Centre), St Thomas' Hospital, London, England

Lupus anticoagulants are a heterogeneous group of autoantibodies detected by their effects on phospholipid-dependent coagulation assays. Persistent lupus anticoagulants are associated with thrombotic disease, but not all are clinically significant. Antibody heterogeneity and reagent and test variability dictate that at least 2 tests, of different types, should be used to screen lupus anticoagulants. The objective of this study was to investigate whether the activated seven lupus anticoagulant assay detects clinically significant antibodies. Eighty-two patients with antiphospholipid syndrome (APS) and 32 with systemic lupus erythematosus + positive for activated seven lupus anticoagulant and who were without thrombosis, who were positive by activated seven lupus anticoagulant assay, were investigated for lupus anticoagulants by dilute Russell's viper venom time, dilute activated partial thromboplastin time, and Taipan snake venom time, and for anticardiolipin antibodies. Fifty-seven of the APS patients were positive for lupus anticoagulants in multiple assays, 25 in activated seven lupus anticoagulant alone. Fourteen of the latter group were previously positive in other antiphospholipid antibodies assays, and 11 had only been positive for lupus anticoagulants by activated seven lupus anticoagulant. Twenty-eight had elevated anticardiolipin antibodies, 6 of whom were from the group that was positive in activated seven lupus anticoagulant only. Eight of the systemic lupus erythematosus + lupus anticoagulants (without thrombosis) patients were positive for lupus anticoagulant by activated seven lupus anticoagulant alone and had only been positive in activated seven lupus anticoagulant previously, and none had elevated anticardiolipin antibodies. The remaining 24 patients were lupus-anticoagulant positive in multiple assays, and 9 had elevated anticardiolipin antibodies. Dilute Russell's viper venom time and Dilute activated partial thromboplastin time are widely used to detect lupus anticoagulants and are considered to detect clinically significant antibodies. Activated seven lupus anticoagulant detected antibodies in APS patients who were positive by these assays and also lupus anticoagulants undetectable by the dilute Russell's viper venom time/dilute activated partial thromboplastin time reagents used, demonstrating its utility as a first-line or second-line assay.

Key Words: activated seven lupus anticoagulant assay • antiphospholipid syndrome • lupus anticoagulants

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?